These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3946663)

  • 21. Serum haloperidol concentrations and clinical response in acute psychosis.
    Miller DD; Hershey LA; Duffy JP; Abernethy DR; Greenblatt DJ
    J Clin Psychopharmacol; 1984 Dec; 4(6):305-10. PubMed ID: 6511996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol.
    McSwain ML; Forman LM
    J Clin Psychopharmacol; 1995 Aug; 15(4):284. PubMed ID: 7593712
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical characteristics of drug induced parkinsonism in psychotic patients].
    Giroud-Benítez JL; López-Suárez RM; Méndez-Chávez A; Vistorte-Pupo A; González-Torres R; López-Jaén I; Pradere-Pensado JC; Enriquez Lescano Gort L; Paz-Sendin L
    Rev Neurol; 2001 Dec 1-15; 33(11):1095-7. PubMed ID: 11785039
    [No Abstract]   [Full Text] [Related]  

  • 24. [Parkinsonian and neurodysleptic syndromes during treatment with neuroleptic drugs].
    Marino A
    Riv Sper Freniatr Med Leg Alien Ment; 1965 Aug; 89(4):892-926. PubMed ID: 5854970
    [No Abstract]   [Full Text] [Related]  

  • 25. [Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up].
    Askenazy F; Dor E; Benoit M; Dupuis G; Serret S; Myquel M; Seddiki Y
    Encephale; 2010 Feb; 36(1):46-53. PubMed ID: 20159196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.
    Schilkrut R; Rüther E; Ackenheil M; Eben E; Hippius H
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):37-42. PubMed ID: 981321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of haloperidol and thioridazine HC1 in chronic treatment-resistant schizophrenics.
    Gonier T; Schiele BC; Vestre ND
    Behav Neuropsychiatry; 1970; 2(3):47-9 passim. PubMed ID: 4913152
    [No Abstract]   [Full Text] [Related]  

  • 28. Rapid control of psychotic excitement states with intramuscular haloperidol.
    Sangiovanni F; Taylor MA; Abrams R; Gaztanaga P
    Am J Psychiatry; 1973 Oct; 130(10):1155-6. PubMed ID: 4728914
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of bormperidol in psychotic outpatients.
    Clarysse HJ
    Acta Psychiatr Belg; 1978; 78(1):129-33. PubMed ID: 347875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [On the position of the butyrophenone derivative Haloperidol in psychiatric treatment].
    Greger J; Glitschka A; Müller K
    Psychiatr Neurol Med Psychol (Leipz); 1968 Jun; 20(7):241-52. PubMed ID: 5731879
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pharmacopsychiatry and iatrogenic parkinsonism].
    Pérez de Francisco C; Garnica Portillo R
    Neurol Neurocir Psiquiatr; 1978; 19(1):53-7. PubMed ID: 30054
    [No Abstract]   [Full Text] [Related]  

  • 32. Plasma haloperidol and clinical response: a role for reduced haloperidol in antipsychotic activity?
    Shostak M; Perel JM; Stiller RL; Wyman W; Curran S
    J Clin Psychopharmacol; 1987 Dec; 7(6):394-400. PubMed ID: 3429700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms.
    Chouinard G; Annable L; Turnier L; Holobow N; Szkrumelak N
    Can J Psychiatry; 1993 Nov; 38 Suppl 4():S114-21. PubMed ID: 8306241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Haloperidol decanoate. Results of an open-ended multicentric study in chronic psychotic states].
    Lemperiere T; Ropert R; Leger JM; Alexandre JY; Clerc G; Darondel A; Delaunay J; Delteil P; Malauzat D; Raynaud J
    Encephale; 1984; 10(5):217-22. PubMed ID: 6519017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Open clinical trial with haloperidol decanoate in patients with psychotic disorders].
    Ellerman LA
    Acta Psiquiatr Psicol Am Lat; 1987 Jun; 33(2):157-62. PubMed ID: 3321918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for drug-induced parkinsonism in tardive dyskinesia patients.
    Hansen TE; Brown WL; Weigel RM; Casey DE
    J Clin Psychiatry; 1988 Apr; 49(4):139-41. PubMed ID: 2895762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse interaction of tacrine and haloperidol.
    Maany I
    Am J Psychiatry; 1996 Nov; 153(11):1504. PubMed ID: 8890692
    [No Abstract]   [Full Text] [Related]  

  • 39. Haloperidol and thioridazine in treatment of chronic schizophrenics.
    Prasad L; Townley MC
    Dis Nerv Syst; 1966 Nov; 27(11):722-6. PubMed ID: 5925664
    [No Abstract]   [Full Text] [Related]  

  • 40. Haloperidol update: 1975.
    Ayd FJ
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):14-22. PubMed ID: 1019142
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.